Estradiol + norethisterone-transdermal - Fournier Pharma

Drug Profile

Estradiol + norethisterone-transdermal - Fournier Pharma

Alternative Names: norethisterone + estradiol-transdermal; Norethisterone + estradiol-transdermal - Fournier; TS 20s

Latest Information Update: 30 Mar 2001

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Fournier Pharma
  • Class Estradiol congeners; Estrenes; Hormonal contraceptives; Hormonal replacements; Norpregnenes; Oral contraceptives; Small molecules
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Menopausal syndrome; Postmenopausal osteoporosis

Most Recent Events

  • 30 Mar 2001 Discontinued-I for Menopausal syndrome in France (Transdermal)
  • 30 Mar 2001 Discontinued-I for Postmenopausal osteoporosis in France (Transdermal)
  • 21 Jun 2000 Ares-Serono is now called Serono
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top